 Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc NASDAQ: LMNL said that it would not be progressing the development of fezagepras for idiopathic pulmonary fibrosis IPF nor hypertriglyceridemia. The Company has completed the Phase 1 MAD trial and continues to analyze the resulting data. 